The first of two AstraZeneca events with Slush brought together global health tech innovators and diverse patient perspectives to help answer the question, ‘How can innovation help rebuild healthcare?’ AstraZeneca’s A.Catalyst Network is leveraging its partnership with Slush to improve experiences, advance access and accelerate better health outcomes through innovation.

The A.Catalyst Network, is the new home of patient-enabled innovation, with more than 20 global hubs, spanning Emerging Markets, Europe, Canada, Japan and the US, each with a unique focus depending on the hub’s local characteristics and needs.

The virtual event ‘How can innovation help rebuild healthcare?’ Provided a platform for innovators to come together to discuss health innovation insights through interactive founder roundtables. Key topics of conversation at the event included:

• The current state of the healthcare innovation landscape, including global unmet needs and trends. Notably focusing on digital evolution and transformation and the opportunities this has enabled for collaboration
• How to build successful companies and overcome common challenges and obstacles which are experienced by startups
• The importance of diverse patient-enabled insights in driving enhanced solutions
• How finding the right fit within partnerships supports the significant ability to amplify innovation in healthcare
• A roundtable event with Chris Genders, Founder, Gendius, Albane Grandjean, Head of Marketing and Clinical Affairs, Gleamer, and Cyrus Chan, Assistant Director, HKSTP, in which they discussed the challenges faced by startups and key opportunities for success

The digital activations, which AstraZeneca is holding in collaboration with Slush, highlight how and why its A.Catalyst Network is looking to support startups, tech innovators and founders in achieving their goals of developing biomedical solutions to improve outcomes for patients.

Miika Huttunen, CEO, Slush, said “Slush is focused on creating change and generating the next generation of entrepreneurs. AstraZeneca’s A.Catalyst Network is a fantastic example of how unique partnerships can make this possible. We are experiencing a real increase in cross-sector convergence, which can cause challenges for alignment, but also provide a significant opportunity to develop better healthcare solutions and meet needs which a lack of collaboration and technological advancement made unmeetable in the past.”

AstraZeneca’s partnership with Slush forms a natural extension to the ground-breaking work they are doing with A.Catalyst Network. Slush and A.Catalyst Network work to bring together thinkers and resources to reimagine how to improve patient outcomes, using connected decision making, knowledge sharing, collaboration, cutting-edge research and development and fostering of innovative technologies. 

AstraZeneca’s second virtual event with Slush on 21 October will explore the practicalities and importance of forging non-traditional partnerships in order to bolster innovation.